Gabapentin Capsule
Product Images NDC 71610-421

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71610-421). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Bottle Label 100 mg (71610 0421 53)

Bottle Label 100 mg (71610 0421 53)
FDA Label Image

Aphena Pharma Solutions (TN)

Aphena Pharma Solutions (TN)
FDA Label Image

Figure 1 (Image 01)

Figure 1 (Image 01)
This appears to be a table or chart with information about pain scores and medication dosages. The mean pain score is listed as 0, with two different medication regimens (Parkod and Gabapentin) listed with their corresponding dose titration periods and fixed dose periods. The table also includes a baseline week and subsequent weeks.*
FDA Label Image

Figure 2 (Image 02)

Figure 2 (Image 02)
This appears to be a chart showing the dose and pain score of patients over a 4-week period. The patients are divided into three groups: a placebo group, a group taking Gabapentin at 1800 mg/day and a group taking Gabapentin at 2400 mg/day. The pain score is depicted on a scale from 0 to 10 and was measured at baseline and at the end of weeks 1-7. The chart shows that the mean pain score in each group decreases over time, and that the group taking the higher dose of Gabapentin had the most significant reduction in pain.*
FDA Label Image

Figure 3 (Image 03)

Figure 3 (Image 03)
FDA Label Image

Cockcroft And Gault Equation (Image 04)

Cockcroft And Gault Equation (Image 04)
FDA Label Image

Gabapentin Structural Formula (Image 05)

Gabapentin Structural Formula (Image 05)
FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Image 09)

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Image 09)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.